HALO - Halozyme Therapeutics Non-GAAP EPS of $0.48 beats by $0.01 revenue of $181.5M misses by $10.55M
- Halozyme Therapeutics press release ( NASDAQ: HALO ): Q4 Non-GAAP EPS of $0.48 beats by $0.01 .
- Revenue of $181.5M (+77.9% Y/Y) misses by $10.55M .
- Record Fourth Quarter Royalty Revenue Increased 69% YOY to $106.0 million; Record Full Year Royalty Revenue Increased 77% YOY to $360.5 million
- Cash, cash equivalents and marketable securities were $362.8 million on December 31, 2022, compared to $740.9 million on December 31, 2021.
- 2023 Outlook: Total revenue of $815 million to $845 million, representing growth of 23% to 28% over 2022 total revenue primarily driven by continued strength in Wave 2 products, including DARZALEX ® SC (daratumumab) and Phesgo ® (pertuzumab, trastuzumab and hyaluronidase) utilizing ENHANZE ® technology, as well as full year auto-injector royalty and product contribution. The Company expects revenue from royalties of $445 million to $455 million, representing growth of 23% to 26%.
- EBITDA of $415 million to $440 million, representing growth of >30% over 2022. EBITDA excludes the impact of amortization costs related to the Antares Pharma acquisition.
- Non-GAAP diluted earnings per share of $2.50 to $2.65, representing growth of >10% over 2022 1 . The Company's earnings per share guidance does not consider the impact of potential future share repurchases.
For further details see:
Halozyme Therapeutics Non-GAAP EPS of $0.48 beats by $0.01, revenue of $181.5M misses by $10.55M